Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Big pharma deal alert: Biohaven has signed a licensing agreement with South Korean drugmaker SK Biopharmaceuticals for its epilepsy drug platform, including the drug Opakalim, in a deal worth up to $795 million. The partnership signals growing international interest in Biohaven's epilepsy pipeline and could expand patient access to the treatment in new markets.
Big pharma deal alert: Biohaven's epilepsy platform heads to South Korea
Biohaven has inked a major licensing agreement with South Korean drugmaker SK Biopharmaceuticals, granting rights to its epilepsy drug platform — including its lead candidate, Opakalim — for up to $795 million. The deal, announced on Wednesday, underscores growing global interest in Biohaven's neurology pipeline.
The partnership positions SK Biopharmaceuticals to develop and potentially commercialize Opakalim in new markets, while providing Biohaven with a significant financial boost to advance its broader drug development efforts.
By the Numbers
Why it matters: Epilepsy remains a significant neurological condition with ongoing unmet treatment needs globally. This deal could accelerate the international reach of Opakalim, potentially bringing a novel therapy to patients in markets where SK Biopharmaceuticals operates.
